Faron Pharmaceuticals Oy reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was EUR 30.94 million compared to EUR 28.73 million a year ago. Basic loss per share from continuing operations was EUR 0.48 compared to EUR 0.52 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.5 GBX | 0.00% | +8.51% | -58.20% |
Apr. 16 | Faron Pharmaceuticals Oy Confirms Plans for the Coming Months | CI |
Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.20% | 114M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- FARN Stock
- News Faron Pharmaceuticals Oy
- Faron Pharmaceuticals Oy Reports Earnings Results for the Full Year Ended December 31, 2023